Inventurus Knowledge Solutions Ltd.
NSE: IKSInventurus Knowledge Solutions Ltd.: A 30-second snapshot
Inventurus Knowledge Solutions (IKS Health) is an IT-services company focused on US healthcare administrative outsourcing, currently trading at ₹1,595 — above both its 50-DMA (₹1,464) and 200-DMA (₹1,567) but 14.96% below its 52-week high. FY26 results reported 20% revenue growth and 48% PAT growth; however, the company carries a debt-to-equity ratio of 34.19, the highest in its IT peer group, with a rising debt trend further amplified by the announced $565 million TruBridge acquisition. The stock trades at a trailing PE of 37.84, ranking last among 6 IT peers on that metric, while 1-year price appreciation stands at 2.16%.
P/E
37.8
Forward P/E
26.1
ROE
—
Debt / Equity
34.19
Profit Margin
+21.7%
Div. Yield
—
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
69/100
News
8 headlines · 5 positive · 0 negative
Inventurus Knowledge Solutions (IKS Health) Reports Robust FY26 Financial Results with 20% Revenue Growth and 48% Surge in Profit After Tax - ANI News
ANI News
Jhunjhunwala family-backed Inventurus to buy US-based Trubridge for $565 mn - VCCircle
VCCircle
Inventurus Knowledge Solutions gains on acquiring TruBridge for $565 million - Business Standard
Business Standard
IKS Health Announces Agreement to Acquire TruBridge to Strengthen Access to Rural and Community-Based Healthcare - Business Wire
Business Wire
IKS Health announces $565‑million TruBridge acquisition to expand US healthcare footprint - TradingView
TradingView
Recent context
- ·IKS announced agreement to acquire TruBridge, a US rural and community healthcare IT company, for $565 million in April 2026, adding scale to its US healthcare outsourcing footprint while materially increasing leverage.
- ·FY26 full-year results (reported May 2026) showed 20% revenue growth and 48% PAT surge, representing acceleration from prior-year levels.
- ·News flow over the review period was entirely constructive (5 positive, 0 negative out of 8 articles), concentrated on the TruBridge deal and the annual results.
Strengths
- +5-year earnings CAGR of 41.2% and revenue CAGR of 24% reflect sustained top- and bottom-line expansion over a multi-year window.
- +FCF-positive in 4 of available years, and a consistency score of 83/100, indicating above-average earnings quality within the available data window.
- +FY26 results showed 48% year-on-year PAT growth alongside 20% revenue growth, both reported in May 2026.
- +Mean analyst rating of 1.75 across 8 analysts (1–5 scale, lower = more constructive); forward PE of 26.06 is meaningfully below the trailing PE of 37.84, reflecting analyst expectation of earnings growth.
Weaknesses
- −Debt-to-equity of 34.19 is the highest in the 6-stock IT peer group by a wide margin; the debt trend is rising, and the $565 million TruBridge acquisition adds further leverage to the balance sheet.
- −Trailing PE of 37.84 ranks 6th of 6 among IT peers, trading at a 46–159% premium to TECHM, HCLTECH, WIPRO, TCS and INFY on this metric.
- −ROE data is unavailable, preventing a complete assessment of leverage-adjusted returns; peers such as TCS (ROE 48.4%) and INFY (ROE 31.4%) provide full comparisons that IKS cannot be benchmarked against.
- −3-month price change of -8.45% signals near-term momentum deceleration despite positive annual and fundamental data; the stock is 14.96% below its 52-week high.
Open questions
- ?Does the $565 million TruBridge acquisition represent a leverage level that existing operating cash flows can service comfortably, and over what time horizon does management expect debt normalisation?
- ?Is the 5-year earnings CAGR of 41.2% driven by organic growth in healthcare IT outsourcing, or does it reflect inorganic acquisitions, and how does the quality of those earnings differ?
- ?At a trailing PE premium of 46–159% to IT peers, what specific growth or margin characteristics of the healthcare-IT niche justify the differential versus large-cap generalist IT?
- ?How has the forward PE compression from 37.84 (trailing) to 26.06 (forward) historically translated into actual reported earnings — and what has been the track record of IKS earnings estimates versus outcomes?
Peer comparison: IT
Ranks 3 of 6 on qualityTechnical state
Current price
₹1,595.30
SMA 50
₹1,464.11
SMA 200
₹1,567.03
RSI (14)
51.6 (neutral)
From 52w high
-15.0%
1Y return
+2.2%
3M return
-8.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highDebt-to-equity of 34.19 is substantially above the IT sector norm; all five peers (TCS, INFY, WIPRO, HCLTECH, TECHM) carry D/E well below 1. Debt trend is flagged as rising across the persistence window. The announced $565 million TruBridge acquisition adds further leverage pressure.
- mediumTrailing PE of 37.84 is the highest in the 6-stock IT peer set, 46% above TECHM (25.26) and 129–159% above TCS (16.66), INFY (14.58), WIPRO (15.15) and HCLTECH (18.42). IKS ranks 6th of 6 on PE.
- mediumROE data is unavailable, making direct peer quality comparison on returns incomplete. With D/E at 34.19 and a rising debt trend, the leverage-adjusted return picture cannot be fully assessed. Quality score of 60 places IKS 3rd of 6 peers.
- low3-month price change of -8.45% contrasts with a 1-year gain of +2.16%, indicating near-term momentum deceleration. The stock remains above both 50-DMA (1,464) and 200-DMA (1,567), but is 14.96% below its 52-week high.
Cross-section contradictions
- FY26 results report 20% revenue growth and 48% PAT surge (per news headlines), and the 5-year earnings CAGR stands at 41.2% with an 83/100 consistency score — yet the trailing PE of 37.84 is the highest among 6 IT peers, several of which (TCS ROE 48.4%, INFY ROE 31.4%) carry stronger balance sheets and higher returns on equity.
- News sentiment is entirely positive across 8 articles (5 positive, 0 negative) over the recent period, yet the 3-month price change is -8.45%, a divergence between news flow tone and near-term price direction.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days